Trial profile

Mann JF et al. Lancet 2008;372:547-53

Decrease in estimated glomerular filtration rate (eGFR) during the trial, from baseline to study end

Mann JF et al. Lancet 2008;372:547-53

Estimated glomerular filtration rate at baseline and changes of eGFR

Mann JF et al. Lancet 2008;372:547-53

Incidence of primary and secondary renal outcomes and of its components

Mann JF et al. Lancet 2008;372:547-53

Kaplan-Meier curves for (A) primary renal outcome (dialysis, doubling of serum

creatinine, anddeath), (B) secondary

renal outcome (dialysis and doubling of

serum creatinine), and (C) dialysis

T=telmisartanR=ramipril

Mann JF et al. Lancet 2008;372:547-53

Relative risk for primary renal outcome in subgroups (A) Comparison of ramipril and telmisartanThe interaction term tests whether there is an interaction

of the subgroup with the two treatment modalities

Mann JF et al. Lancet 2008;372:547-53

Relative risk for primary renal outcome in subgroups (B) Comparison of ramipril and telmisartan plus ramipril

The interaction term tests whether there is an interaction of the subgroup with the two treatment modalities

Mann JF et al. Lancet 2008;372:547-53

Changes in log urine albumin to creatinine ratio

Mann JF et al. Lancet 2008;372:547-53